Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for HLA-DRB5 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HLA-DRA/HLA-DRB5 Heterodimer Recombinant Protein HEK293 Expressed (Native Glycosylation), High Purity (>95%), Endotoxin Controlled (<1 EU/μg), Sequence Verified. Ideal for SPR/BLI binding assays. |
View HLA-DRB5 Products |
| Gene Delivery | HLA-DRB5 Promise-ORF / Lentivirus Full-length ORF lentiviral particles designed for stable cell line construction to preserve native conformation in cell-based assays. |
View HLA-DRB5 Products |
| Benchmark Ab | Anti-HLA-DR Recombinant Antibody (Clone L243 Biosimilar) Recombinant positive control antibody for flow cytometry and functional blocking assays. |
View HLA-DRB5 Products |
| Validator | HLA-DRB5 siRNA Set Target-specific siRNA pool for gene knockdown verification and specificity validation. |
View HLA-DRB5 Products |
| Related Target A | HLA-DRA The obligate alpha-chain partner required to form functional HLA-DR heterodimers for antigen presentation studies. |
View HLA-DRA Products |
| Related Target B | HLA-DRB1 High-homology family member essential for counter-screening to ensure drug candidate specificity and avoid off-target toxicity. |
View HLA-DRB1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Heterodimer Stability | Co-expressed HLA-DRA/HLA-DRB5 stable heterodimers with verified theoretical molecular weight. |
| Subfamily Off-Target Cross-Reactivity | Homolog panel including HLA-DRB1 and HLA-DRB3/4/5 strictly verified by mass spectrometry and sequence analysis. |
| Lack of Controls | Clinical benchmark antibodies (L243 biosimilar) included for assay standardization. |
| False Positives in Screening | Validated siRNA sets included for target knockdown and specificity verification. |
Live HLA-DRB5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of HLA-DRB5 is gaining significant traction, particularly due to its strong genetic linkage with HLA-DRB1*15:01 in Multiple Sclerosis (MS) and its emerging role in presentation of tumor-associated neoantigens. The race for HLA-DRB5 therapeutics is intensifying, with major players shifting focus from traditional non-selective immunosuppressive mAbs to antigen-specific tolerogenic therapies and TCR-like (TCRm) antibodies. As first-generation therapies reach the clinic, the next wave of R&D is targeting highly selective HLA-DRB5/peptide complex binders to minimize systemic immune suppression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-like Antibodies (TCRm) | Immunocore, Roche, academic spin-offs | Oncology (Neoantigen-specific immunotherapy) | Affinity & Specificity Assay (Requires high-purity monomeric HLA-DRB5/peptide complexes) |
| Monoclonal Antibodies (mAbs) | Biogen, Novartis | Multiple Sclerosis, Autoimmune Diseases | Epitope Mapping (Requires sequence-verified HLA-DRB5 and HLA-DRB1 panels) |
| Tolerogenic Vaccines / Dendritic Cell Therapies | Anokion, Cour Pharmaceutical | Neurodegenerative Autoimmunity | Antigen Presentation Validation (Requires stable HLA-DRB5-expressing Lentivirus cell lines) |